Point72 Middle East FZE’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-5,200
Closed -$645K 403
2023
Q4
$645K Sell
5,200
-2,500
-32% -$255K 0.02% 742
2023
Q3
$718K Buy
7,700
+5,000
+185% +$564K 0.02% 685
2023
Q2
$347K Buy
2,700
+1,500
+125% +$181K 0.01% 886
2023
Q1
$139K Sell
1,200
-3,000
-71% -$336K ﹤0.01% 1034
2022
Q4
$476K Buy
+4,200
New +$461K 0.02% 747

Other funds holding DXCM

Point72 Middle East FZE's DXCM Position: Q1 2024 in Review

Point72 Middle East FZE sold out of DexCom (DXCM) in Q1 2024, closing a stake of 39,190 shares — an estimated $4.86M sold.

Point72 Middle East FZE first reported a position in DXCM in Q4 2022 and held it in 5 quarters. The position peaked at $16.3M in Q3 2023. 1,032 funds tracked by Wall St. Rank hold DXCM as of Q1 2024.

  • Point72 Middle East FZE reported no remaining DexCom position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 39,190 DexCom shares in Q1 2024, an estimated $4.86M.
  • Point72 Middle East FZE first reported a position in DexCom in Q4 2022 and held it in 5 quarters.
  • Point72 Middle East FZE's DexCom position peaked at $16.3M in Q3 2023.
  • 1,032 funds tracked by Wall St. Rank held DexCom as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.